Back to news
Orakl Oncology raises $34m to test cancer drugs on ‘virtual patients’
MULTIPLE REPORTS·Published ·Main source · Sifted
Story essentials
Orakl Oncology
Europe
November 2026
Original reports
Orakl Oncology has secured $34 million in funding.
The company focuses on testing cancer drugs using 'virtual patients' simulations.
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policyRead next
Prioritized by shared people, places, and events.
President Trump supports calls for Jensen Huang's reinstatement at Nvidia
President Donald Trump has expressed support for calls to reinstate Jensen Huang as CEO of Nvidia. The company's board is currently conducting a search for leadership.